(S)-2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid

ID: ALA571492

Chembl Id: CHEMBL571492

PubChem CID: 15384271

Max Phase: Preclinical

Molecular Formula: C21H24N2O4

Molecular Weight: 368.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O

Standard InChI:  InChI=1S/C21H24N2O4/c1-12-7-16(24)8-13(2)17(12)10-18(22)20(25)23-11-15-6-4-3-5-14(15)9-19(23)21(26)27/h3-8,18-19,24H,9-11,22H2,1-2H3,(H,26,27)/t18-,19-/m0/s1

Standard InChI Key:  QBLVXTMPLLWZDE-OALUTQOASA-N

Alternative Forms

Associated Targets(Human)

OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Opioid receptors; mu & delta (1530 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Oprd1 Delta opioid receptor (3911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Oprm1 Mu opioid receptor (6060 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Oprd1 Delta opioid receptor (3127 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Mu opioid receptor (3620 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Oprd1 Opioid receptors; mu & delta (878 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Kappa opioid receptor (4577 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 mu/kappa opioid receptor (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 368.43Molecular Weight (Monoisotopic): 368.1736AlogP: 1.92#Rotatable Bonds: 4
Polar Surface Area: 103.86Molecular Species: ACIDHBA: 4HBD: 3
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 3.69CX Basic pKa: 8.04CX LogP: 0.63CX LogD: 0.55
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.76Np Likeness Score: 0.06

References

1. Pagé D, McClory A, Mischki T, Schmidt R, Butterworth J, St-Onge S, Labarre M, Payza K, Brown W..  (2000)  Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists.,  10  (2): [PMID:10673103] [10.1016/s0960-894x(99)00652-6]
2. Salvadori S, Balboni G, Guerrini R, Tomatis R, Bianchi C, Bryant SD, Cooper PS, Lazarus LH..  (1997)  Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.,  40  (19): [PMID:9301674] [10.1021/jm9607663]
3. Salvadori S, Balboni G, Guerrini R, Tomatis R, Bianchi C, Bryant SD, Cooper PS, Lazarus LH..  (1997)  Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.,  40  (19): [PMID:9301674] [10.1021/jm9607663]
4. Balboni G, Guerrini R, Salvadori S, Bianchi C, Rizzi D, Bryant SD, Lazarus LH..  (2002)  Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.,  45  (3): [PMID:11806723] [10.1021/jm010449i]
5. Fujita Y, Tsuda Y, Motoyama T, Li T, Miyazaki A, Yokoi T, Sasaki Y, Ambo A, Niizuma H, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y..  (2005)  Studies on the structure-activity relationship of 2',6'-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3).,  15  (3): [PMID:15664820] [10.1016/j.bmcl.2004.11.040]
6. Li T, Fujita Y, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Salvadori S, Lazarus LH, Okada Y..  (2005)  Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.,  48  (25): [PMID:16335927] [10.1021/jm050377l]
7. Li T, Shiotani K, Miyazaki A, Fujita Y, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH, Okada Y..  (2005)  New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.,  15  (24): [PMID:16183273] [10.1016/j.bmcl.2005.08.073]
8. Berezowska I, Chung NN, Lemieux C, Wilkes BC, Schiller PW..  (2009)  Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1).,  52  (21): [PMID:19827750] [10.1021/jm9004913]
9. Ballet S, Marczak ED, Feytens D, Salvadori S, Sasaki Y, Abell AD, Lazarus LH, Balboni G, Tourwé D..  (2010)  Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds.,  20  (5): [PMID:20137938] [10.1016/j.bmcl.2010.01.055]
10. Weltrowska G, Nguyen TM, Chung NN, Wilkes BC, Schiller PW..  (2013)  N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.,  23  (18): [PMID:23932788] [10.1016/j.bmcl.2013.07.036]

Source